Skip to content

To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)

To Study the Clinical Characteristics and Treatment Outcome of COVID-19 Patients Admitted in Hospitals of Max Healthcare (SCOPe Study)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04367064
Acronym
SCOPe
Enrollment
1000
Registered
2020-04-29
Start date
2020-04-25
Completion date
2020-12-25
Last updated
2020-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID

Brief summary

This is an observational study for Corona virus disease by the Max Healthcare.Corona virus 2019 disease (COVID-19) is a respiratory tract infectious disease caused by a newly emergent corona virus. This virus is linked to the same family of viruses as Severe Acute Respiratory Syndrome (SARS) and some types of common cold.

Detailed description

In view of increasing cases in India and the possibility of the exponential rise of cases, study has been designed to observe the patient profile and outcomes for hospitalized positive Covid-19 patients that may help to understand the effectiveness of different treatment strategies. This is a retrospective and prospective, observational study based on collection of data related to COVID-19 admitted patients treated in the hospitals of Max Healthcare as per the standard treatment protocol and policy for COVID 19 at Max Healthcare. Covid19 patients shall be approached at the time of admission for participation in this study. If the patient consents, the participating investigator or designated study personnel will collect the baseline demographic details of the patient, along with medical history; current disease status; current and previous treatment details; and the results of all the laboratory tests performed, as per the standard clinical practices. Daily follow up will be done on a structured case record form (CRF) till the discharge or death.

Interventions

None listed

Sponsors

Max Healthcare Insititute Limited
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Patients of either sex aged ≥18 years 2. Patients who are Covid-19 positive 3. All patients with positive Corona virus infection admitted in the hospitals of Max Healthcare will be included in the study.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
we will compare the clinical outcome of the COVID 19 patients with their age and gender3-4 monthsCollection of the baseline demographic details of the patient, along with medical history; current disease status; current and previous treatment details; and the results of all the laboratory tests performed, as per the standard clinical practices. All the data will be entered into Excel sheet, row wise for each patient. For studying the demographic profile, the age will be divided into standard 10-year intervals and percentages will be obtained for each sex and combined for males and females. This will be in addition to the mean and SD of age.

Secondary

MeasureTime frameDescription
we will compare the effect of different treatments given to the COVID 19 patients at Max Hospital3-4 monthsDaily follow up will be done on a structured case record form (CRF) till the discharge or death of the subject. Treatment-Related Adverse Events as Assessed by CTCAE v4.0 will be captured in CRF. Clinical profile and outcome will be analyzed separately for each treatment regimen after suitable grouping of the regimens. Statistical significance of the association of outcomes with the clinical profile and treatment regimens will be checked with chi-square test or Fisher exact test in case the numbers are small. Effectiveness of each regimen will also be checked for significance of difference with chi-square test. A P-value \<0.05 will be considered statistically significant but the final conclusion will be based on corroborative evidence and factors such as clinical profile. SPSS 20 will be used for all the calculations.

Countries

India

Contacts

Primary ContactSandeep Budhiraja, MRCP, FACP
sbudhiraja@maxhealthcare.com9810262954
Backup ContactRam Shankar Mishra, DNB, FRCP
docmishra@yahoo.co.in9810193145

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026